Bioclinica acquires clinical research company

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/maxsattana)
(Image: iStock/maxsattana)

Related tags: Clinical trial, Clinical research

The acquisition of Compass Research expands Bioclinica’s access to several specialized populations with neurodegenerative disorders and other diseases.

"The Compass Research acquisition marks Bioclinica’s entry into the U.S. investigator site network​," Bioclinica CEO, John Hubbard, told Outsourcing-Pharma.com.

Compass Research will become part of Bioclinica’s Research Network Division, which is part of the Global Clinical Research Business Segment. 

"The Bioclinica Research Network has sites on three continents with plans to rapidly expand in the United States and other areas​," added Hubbard.

The Orlando, Florida-based clinical research company’s position in the state – specifically its presence in the largest retirement community in the US – will provide Bioclinica with access to 179,000 elderly residents who could contribute to research, including arthritis, back, knee and hip pain, Alzheimer’s Disease, dementia, cardiovascular diseases, among others.

Compass Research has also curated a database​ through its physician network and affiliate practices with in-clinic recruiters, which includes nearly 80,000 potential subjects.

"This acquisition of Compass Research brings established, highly successful U.S. investigational sites into Bioclinica’s global research network​," said Hubbard.

According to Bioclinica, the leadership team at Compass will play a strategic role in the company’s research network expansion.

"Compass will be joining a global research network with sites in Latin America, Europe, and Asia and will be a driving force in Bioclinica’s expansion into the United States​," added Hubbard.

In addition to expanding the company’s research network, Hubbard said that the companies “see unique synergies​” with its Medical Imaging, Biomarkers​, eHealth Solutions, and Patient Recruitment-Retention teams.

As Outsourcing-Pharma.com previously reported​, Bioclinica is actively partnering to provide innovative offering models and technologies.

Most recently, the company launched a new clinical trial management system (CTMS) for contract research organizations (CROs) and mid-market biopharma. It also announced​ an agreement to become ArisGlobal's preferred partner to support a "continuum of pharmacovigilance services​."

"As with our other recent acquisitions, the primary goal in the near term is for a successful integration, ensuring no disruption to ongoing projects​," explained Hubbard.

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

Related suppliers

Follow us

Products

View more